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Data on the burden of disease and circulation patterns of inﬂuenza B lineages for Brazil are
limited. This review aims to describe the pattern of inﬂuenza B occurrence in Brazil to have
a  better understanding of its epidemiology and its relevance when considering seasonal
inﬂuenza vaccine composition.
A review of the data including analysis of international and local surveillance data as well
as  information from online search of databases using Medical Subject Headings terms in
conjunction with screening of abstracts from scientiﬁc events was performed.
Based on international epidemiologic surveillance data, moderate levels of inﬂuenza B dis-
ease  (19%; 2006–2014) were observed. Of these nine years, it was possible to compare data
from three years (2007, 2008 and 2013) which have information on the circulating inﬂuenza B
lineage. Co-circulation of inﬂuenza B lineages was observed in all these three inﬂuenza sea-
sons,  of which, during one season, a high degree of mismatch between the vaccine lineage
and  the predominant circulating lineage (91.4% [2013]) was observed. Local surveillance data
reveal a distinct and dynamic distribution of respiratory viruses over the years. Data from
published literature and abstracts show that inﬂuenza B is a signiﬁcant cause of disease
with an unpredictable circulation pattern and showing trends indicating reemergence of
the B/Victoria lineage. The abstracts report notable levels of co-circulation of both inﬂuenza
B  lineages (2000–2013). Mismatch between the Southern hemisphere vaccine and the most
prevalent circulating viruses in Brazil were observed in ﬁve inﬂuenza seasons.
The evidence on co-circulation of two inﬂuenza B lineages and mismatched seasons in
Brazil indicates the beneﬁt of quadrivalent inﬂuenza vaccines in conferring broader seasonalinﬂuenza protection. Add
important for monitoring
vaccination.
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Introduction
Inﬂuenza is a highly infectious acute viral illness resulting in
signiﬁcant morbidity as well as healthcare resource utiliza-
tion. In healthy individuals inﬂuenza is generally self-limiting,
but can often cause complications.1,2 There are 3 types of
seasonal inﬂuenza viruses – A, B, and C. Inﬂuenza A causes
moderate to severe illness and affects individuals of all age
groups. Inﬂuenza B can cause disease of similar severity as
inﬂuenza A, and even though the morbidity is higher in chil-
dren, all age groups can be affected.3,4 The inﬂuenza B virus
is more  stable than inﬂuenza A, with less antigenic drift and
consequent immunologic stability, and does not undergo the
process of antigenic shift. Inﬂuenza C is rarely reported as
a cause of human illness, probably because most cases are
subclinical.5 Both inﬂuenza A and B cause annual epidemics
worldwide and are estimated to result in 3–5 million cases of
severe illness, and 250,000–500,000 deaths.6
Inﬂuenza vaccination is the most important prophylactic
intervention against infection. Until the 2012–2013 inﬂuenza
season, use of trivalent inactivated inﬂuenza vaccines, con-
taining two inﬂuenza A strains (A[H1N1] and A[H3N2]) and
one inﬂuenza B lineage (B/Yamagata or B/Victoria) was rec-
ommended for use in immunization programs by the World
Health Organization (WHO).6 As inﬂuenza viruses undergo
frequent changes in their surface antigens, new inﬂuenza vac-
cines are designed annually to match the circulating virus
subtype expected for the next inﬂuenza season.7 The selection
of the inﬂuenza B lineage is considered critical in determining
the effectiveness of vaccination programs.7 Unfortunately, the
correct prediction of the predominating circulating B lineage
is quite difﬁcult, often leading to inaccuracies in prediction,
causing a mismatch between the recommended vaccine lin-
eage and the circulating inﬂuenza B lineage. Prior studies
have raised concerns that mismatches can result in lower
vaccine effectiveness, due to the absence of cross-protection
between antigenically distinct inﬂuenza B lineages, leading
to more  inﬂuenza cases,8,9 and an increase in inﬂuenza-
related medical resource utilization and costs.2,10 In addition
to this, Matias et al.11 have found that inﬂuenza B-associated
mortality could serve as a surrogate marker of disease
severity.
In the Latin America and Caribbean region, seasonal
inﬂuenza causes high morbidity placing a substantial eco-
nomic burden on healthcare systems and society.12 Data
on the burden of inﬂuenza disease for Brazil are limited,
most likely due to underreporting.12 Between 2000 and
2008, data from the inﬂuenza surveillance system in Brazil
revealed that inﬂuenza-like illness (ILI) led to a total of
4.39–16.92% of hospital consultations, and in 2008, of all posi-
tive reported inﬂuenza cases, 43.29% (95% CI: 37.59–49.13) were
inﬂuenza B.12
The Ministry of Health (MoH, “Ministério da Saúde”) of
Brazil promotes annual national inﬂuenza vaccination cam-
paigns. Over the years, there has been a gradual expansion
of the recommended groups for annual inﬂuenza immu-
nization in Brazil.13 Since 1999, inﬂuenza vaccination was
introduced for elderly people aged above 65 years and
other groups vulnerable to complications (patients with 0 1 6;2  0(1):81–90
co-morbidities). In the year 2000, individuals 60 years or older
were included for vaccination.14,15 During 2011–2012, in addi-
tion to elderly people, vaccination was extended to children
aged six months to those aged below two years, pregnant
women, healthcare professionals, and indigenous people. In
2013, women after child birth, individuals with chronic dis-
ease and transplant, and individuals in detention facilities
were included for annual inﬂuenza vaccination. In 2014, chil-
dren aged 2–4 years were also included in the recommended
target at-risk groups for vaccination. The information sys-
tem of National Immunization Program for Brazil (“Programa
Nacional de Imunizac¸ão”)13 reported that across all target
vaccination groups, overall mean vaccination coverage of
86.8% was reached in 2014.13 During all inﬂuenza vaccination
campaigns in Brazil, trivalent vaccines were used accord-
ing to WHO  recommended vaccine composition for South
hemisphere.16
Although high vaccination coverage levels have been
reached in these target vaccination groups, little is known
about the effectiveness of vaccination programs in Brazil.14,17
A number of factors, in particular vaccine coverage, is known
to inﬂuence the effectiveness of inﬂuenza vaccination pro-
grams. However, the Brazilian MoH data shows vaccine
coverage to be high in almost all years since the introduc-
tion of vaccination. Importantly, the extent to which the
vaccine recommended inﬂuenza B virus lineage matches the
inﬂuenza virus lineage circulating in the population during
an inﬂuenza season is known to impact the effectiveness of
seasonal inﬂuenza vaccination programs.14 Data on labora-
tory surveillance of the inﬂuenza B virus in Brazil are limited,
speciﬁcally data on the burden of disease and circulation pat-
terns of inﬂuenza B lineages. The present integrative review
of publicly available data aims to consolidate ﬁndings on the
pattern of inﬂuenza B occurrence in Brazil to have a better
understanding of inﬂuenza B epidemiology and its relevance
to seasonal vaccine composition.
Material  and  methods
Information  sources  and  search  strategy
Epidemiological  surveillance  systems
Different sources were used to retrieve information on epi-
demiological surveillance. We referred to international data
sources to check WHO  recommendations on the vaccine com-
position in the Southern hemisphere,18 and information on
circulating inﬂuenza lineages for Brazil, the South America
region and globally from the WHO/FluNet database which pro-
vides data through its network – Global Inﬂuenza Surveillance
and Response System (GISRS) laboratories.19 Consolidation of
available national epidemiological information on Inﬂuenza
in the Epidemiological Bulletins of the Brazilian MoH  was
also performed. Bulletins available from 2009 to Epidemiolog-
ical Week 35 of 2014 were considered.15 In Brazil, two  typessal Severe Acute Respiratory Syndrome (SARS) surveillance.
ILI is deﬁned as fever followed by cough or sore throat and
symptoms onset within the last seven days. SARS is deﬁned
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s fever followed by cough or sore throat and experiencing
yspnea, requiring hospitalization. Oxygen saturation lev-
ls lower than 95%, respiratory distress, or respiratory rate
ncrease, are also considered in SARS. The sentinel ILI surveil-
ance, which has a network of units distributed throughout
he country’s geographic regions, is used in the identiﬁca-
ion and characterization of circulating respiratory viruses
n viral isolations. The universal SARS surveillance, which
as implemented post-identiﬁcation of the inﬂuenza A(H1N1)
009 pandemic strain (pdm09), monitors hospitalized cases
nd deaths. In both systems, data are collected by means
f standardized forms and entered into the online informa-
ion systems: Inﬂuenza epidemiological surveillance system
alled SIVEP-Gripe for ILI cases, and the National Informa-
ion System for Notiﬁable Diseases known as SINAN Inﬂuenza
eb for SARS cases. Results from tests performed at the
7 Public Health Central Laboratories (“Laboratórios Centrais
e Saúde Pública, Lacen”) are routinely included in these
ystems. The diagnostic kits currently available identify the
nﬂuenza A(H1N1)pdm09 viral strain (determined by WHO),
nﬂuenza A(H3N2), inﬂuenza A not subtyped, and inﬂuenza
 virus. The antigenic characterization of the circulating
nﬂuenza virus lineage is performed by three laboratories in
razil (“Instituto Evandro Chagas” – Pará, “Instituto Adolfo
utz”, São Paulo and “Instituto Oswaldo Cruz”, Rio de Janeiro).
hese laboratories are part of a network of 140 National
nﬂuenza Centers acknowledged by WHO  as members of the
ISRS.
nline  literature  search  and  review  of  abstracts
n integrative literature review was performed using online
atabase tools such as PubMed/MEDLINE, Lilacs and Scielo.
earches on online databases were conducted using the fol-
owing search strategy built for the PubMed database (via
edical Subject Headings [MeSH] controlled vocabulary) and
djusted for other databases according to their speciﬁcities:
(((((inﬂuenza [Title/Abstract]) OR inﬂuenzae)) OR ((orthomyx-
viridae [MeSH Major Topic]) OR inﬂuenza, human [MeSH
ajor Topic]))) AND Brazil”. Studies on inﬂuenza B, with Brazil
s the place of study and those with virological inﬂuenza
 information were considered. Articles published between
007 and 2014 were considered and a language constraint
as not applied. Articles and abstracts with general inﬂuenza
eports or without subtyping (A or B) were not included.
ne reviewer screened titles and abstracts for relevance, as
he deﬁned inclusion criteria were restrictive. An additional
esearch was conducted in abstracts of the Annals of Scien-
iﬁc Events related to the area of research. A total of 10 events
ere considered.20–29 All authors agreed with the selected
ublications.
nalysesata on viral lineage isolation and characterization, vac-
ination campaign, viral lineage surveillance and strain
atch-mismatch from different sources were collected and
onsolidated. Statistical analysis was not performed, and thus
ll data are descriptive. 1 6;2  0(1):81–90 83
Results
Inﬂuenza  viral  strain  data
Epidemiologic  surveillance  systems
Information on inﬂuenza A and B subtype patterns were
obtained from the WHO/FluNet database (up to epidemi-
ological week 35, 2014). Globally and for South America,
1,122,415 and 95,040 samples were recorded in the database
(WHO/FluNet-GISRS), respectively; of these 45,856 and 937
samples were typed as inﬂuenza B. In South America, of 937
inﬂuenza B samples, only 279 were subtyped, of which 252
(90.3%) samples were of the B/Yamagata lineage and 27 (9.7%)
were subtyped as the B/Victoria lineage. In comparison, the
WHO/FluNet database recorded 7756 samples from Brazil of
which 100 samples were positive for the inﬂuenza B virus.
Among these no inﬂuenza B sample was subtyped.
Epidemiologic surveillance data showed that the inﬂuenza
B disease burden was moderate in both South America and
Brazil. Based on WHO/FluNet (September 07, 2014), in Brazil,
between 2006 and 2014, inﬂuenza B circulated in all the years,
with an average of 19% of all circulating inﬂuenza viruses (A
and B), varying from 1.0% to 42.6% (2006: 21.8%; 2007: 27.5%;
2008: 42.6%; 2009: 1.0%; 2010: 14.0%; 2011: 15.5%; 2012: 8.9%;
2013: 30.6% and 2014: 10.2%). In South America, between 2006
and 2014, a similar trend was observed. Inﬂuenza B virus cir-
culated in all the years, with an average 16% of inﬂuenza B
detected in relation to all of the circulating inﬂuenza viruses
(A and B), varying from 0.5% to 30.1% (2006: 14.0%; 2007: 12.6%;
2008: 30.1%; 2009: 0.5%; 2010: 16.9%; 2011: 4.2%; 2012: 28.3%;
2013: 19.6% and 2014: 14.0%).
Trends on the etiological distribution of inﬂuenza disease
were studied from the Epidemiological Bulletins of the Brazil-
ian MoH  based on two types of surveillance systems. Data
from the Sentinel Surveillance of ILI (2009–2014) shows a
dynamic pattern of distribution of different respiratory viruses
in Brazil through the years, by epidemiological week, with pre-
dominance of inﬂuenza and respiratory syncytial virus (RSV).
Inﬂuenza virus circulation demonstrates a seasonal pattern
with highest occurrence from April to June, while RSV circu-
lation showed more  intense activity in the ﬁrst months of the
years. Inﬂuenza B follows similar seasonal trends; however
it seems to occur slightly later than inﬂuenza A. During the
seasons of 2009, 2010, 2011 and 2012, inﬂuenza A and RSV
predominated followed by inﬂuenza B. In the year 2013, the
absolute numbers of inﬂuenza B typed samples in ILI cases
was higher (n = 727; 36.2% [2013]) compared to the previous
years (n = 128; 21.0% [2009], n = 213; 46.3% [2010], n = 191; 34.5%
[2011], n = not available [2012]) and 2014 (n = 150; 12.7% [2014,
up to epidemiological week 35]). There were regional differ-
ences in the seasonal patterns of inﬂuenza virus, however
strain speciﬁc information is lacking.
Data on virus circulation by age group (2013, Fig. 1) shows
that inﬂuenza A(H1N1)pdm09 virus was predominant in indi-
viduals aged 30–59 years, especially among individuals aged
40–49 years of age (37.4%). On the other hand, inﬂuenza B virus
was predominant in younger people, aged 5–29 years, with
highest proportions observed in children aged 5–9 years and
10–19 years (34.9% and 34.6%, respectively).
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Fig. 1 – Distribution of the respiratory viruses identiﬁed in sentinel units of ILI by age group, Brazil, 2013. Note: Data
 (01obtained from ILI Sentinel Surveillance, SIVEP/Gripe/SVS/MS
The pattern of hospitalized SARS cases from the Univer-
sal SARS surveillance showed that in 2013, although inﬂuenza
A(H1N1)pdm09 was predominant, 22.5% of SARS cases pos-
itive for inﬂuenza (1337/5935, with 85 deaths) were caused
by the inﬂuenza B virus. Regional variation was observed
between the regions – South region (29%) and North region
(12%). In 2014 (up to epidemiological week 35) 6% of SARS cases
positive for inﬂuenza (75/1307, with 9 deaths) were caused by
the inﬂuenza B virus (Table 1).
Online  literature  search
A total of 722 articles were identiﬁed, of which 602 articles
were excluded after the review of titles as they were related to
inﬂuenza other than inﬂuenza B. Subsequent to the screening
of titles, abstracts of the 120 potentially relevant articles were
reviewed and, as a result, 108 articles were excluded when
the eligibility criteria were not met  (Fig. 2). In all, 12 articles
presenting evidence on inﬂuenza B virus circulation in Brazil
30–41for the years 1996–2013 were included. Details for each of
the studies are shown in Supplementary File 1.
Two studies detailed characteristics of an inﬂuenza out-
break in February 2012 on cruise ships.32,35 Fernandes et al.35
Table 1 – Percentage of SARS cases positive for inﬂuenza accord
year, Brazil.
North Northeast South
Up to epidemiological week 52/2013
Inﬂuenza A 88.3 79.0 80
Inﬂuenza B 11.7 21.0 20
Up to epidemiological week 35/2014
Inﬂuenza A 86.5 89.8 94
Inﬂuenza B 13.5 10.2 5
Note:  Data obtained from Sinan Inﬂuenza Web/SVS/MS; SARS, Severe Acut March, 2014); ILI, inﬂuenza-like illness
reported ﬁndings from the ﬁrst inﬂuenza outbreak detected
by Brazilian public health authorities in a vessel cruising in
South America. Of 11 hospitalized cases of acute respiratory
illness, there were six cases with inﬂuenza B virus detected in
the nasopharyngeal isolates.35 In another study by Borborema
et al.32, it was shown that the inﬂuenza B virus was the cause
of the outbreak (detected in seven individuals with respiratory
illness).
Other reports from the online literature review were
primarily from retrospective descriptive studies. Freitas36
showed that inﬂuenza B was attributable to moderate levels of
disease during 2000 and 2010 (3–17%), and its occurrence was
notable in the South and Central-West regions. Paiva et al.37
conﬁrmed the reemergence of the B/Victoria viruses in São
Paulo, Brazil, during the years 1996–2012.
Review  of  abstracts
A total of three abstracts from Annals of Scientiﬁc Events,
42–44in their periodic issues from 2007 to 2014 were selected
(Supplementary File 1). Perosa and Bellei44 studied inﬂuenza
B circulation patterns during 12 seasons (2001–2013) for São
Paulo city and identiﬁed that of 96 samples subtyped in
ing to identiﬁed virus type by region of residence and
east South Central-West Brazil
.0 70.9 85.0 77.5
.0 29.1 15.0 22.5
.9 94.5 94.6 94.3
.1 5.5 5.4 5.7
e Respiratory Syndrome.
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(Fig. 2 – Flowchart of artic
atients (mean age: 23.9 years), the majority of samples
ad the B/Victoria lineage (58.3%) and the remaining 41.7%
elonged to the B/Yamagata lineage.44 Oliveira et al.42 studied
ismatch between vaccine and circulating inﬂuenza lin-
ages in different regions of Brazil between 2001 and 2013
nd observed varying levels of co-circulation (up to 100%) of
nﬂuenza B lineages.42 A study by Paiva et al.43 showed that
cross different regions of Brazil, 16% of inﬂuenza in clini-
al specimens from sentinel units in 2013 were caused by the
/Victoria lineage while the remaining cases were caused by
he inﬂuenza A virus.
nﬂuenza  B  lineage  match-mismatch  in  Brazil
pidemiologic  surveillance  systems
n Table 2, based on WHO/FluNet reports, consolidated annual
ata on the lineages that were part of the vaccine, the propor-
ion of predominant circulating lineages and the proportion of
ineage mismatch is shown for South America and Brazil. Data
or Brazil was available for nine years; of these, it was only pos-
ible to compare data from three years (2007, 2008 and 2013)
hich have information available on the circulating inﬂuenza
 virus lineage. In Brazil, co-circulation of both inﬂuenza B lin-
ages was detected in all these three inﬂuenza seasons, and a
igh level of mismatch (91.4%) was observed in one year (2013)
Table 2). In the same year for South America 52.0% (2013) of
ismatch was observed.
nline  literature  search  and  review  of  abstracts
one of the articles from the online literature search in par-
icular studied inﬂuenza B lineage match-mismatch in Brazil.
owever, from the reviewed abstracts, all three focused on
 lineage match-mismatch in Brazil.42–44 Overall, mismatch
evels in the range 0–100% were observed between the circu-
ating inﬂuenza B virus lineage and the vaccine recommended
ineage in Brazil and São Paulo city between 2000 and 2013
Oliveira et al.42 and Perosa and Bellei44) (Fig. 3). Oliveira et al.42lection from 3 databases.
showed that the B/Victoria and B/Yamagata lineages have co-
circulated in Brazil since 2005. Key mismatches between the
WHO  recommended Southern hemisphere vaccine composi-
tion and the most prevalent circulating viruses in Brazil were
observed in the years 2002 (100%), 2005 (67%), 2008 (65%), 2010
(72%) and 2013 (91%).42 A separate dataset on inﬂuenza B cir-
culation from the São Paulo city also showed a high degree
of mismatch in three seasons i.e. years 2002 (75%), 2010 (91%)
and 2013 (100%)44 (Fig. 3). Moderate levels of regional varia-
tion across Brazil were evident (data not shown). Paiva et al.43
reported a complete mismatch (100%) between the circulat-
ing inﬂuenza B virus lineage and the vaccine recommended
lineage in the 2013 inﬂuenza season in different regions of
Brazil.
Discussion
Data on inﬂuenza B disease burden for Brazil are limited, espe-
cially with regards to inﬂuenza B disease burden and subtypes,
which are important when considering the use of inﬂuenza
vaccines. In this review, we aimed to summarize the available
evidence base on inﬂuenza B disease patterns in Brazil in the
international and local public health databases, as well from
the literature and plenary scientiﬁc events. The review of these
data highlights important patterns of inﬂuenza B circulation
in Brazil. Based on WHO/FluNet reports, moderate levels of
inﬂuenza B burden (1.0–42.6%) were observed over nine years,
with the exception of 2009 (1.0%), which could potentially
have been due to the displacement of inﬂuenza B circulation
resulting from the inﬂuenza A pandemic in 2009. This ﬁnding
indicates the unpredictability of inﬂuenza B circulation.
Based on WHO/FluNet reports, it was possible to compare
data from only three years during 2006–2014 (2007, 2008 and
2013) which have information on the circulating inﬂuenza
B virus lineages. Signiﬁcant levels of co-circulation of both
inﬂuenza B virus lineages during the three inﬂuenza seasons
between 2006 and 2014 were observed. These data indicate
86  b r a z j i n f e c t d i s . 2 0 1 6;2  0(1):81–90
Table 2 – Comparison of inﬂuenza virus vaccine lineage and circulating lineage in the population, South America and
Brazil, 2006–2014 (WHO/FluNet).
Reference Predominant lineage (n; %)a Vaccine Recommendation % Mismatchb
2006
South America – Victoria –
Brazil – Victoria –
2007
South America Victoria (5; 0.2) Victoria 28.6
Brazil Victoria (5; 6.3) Victoria 28.6
2008
South America Yamagata (46; 2.1) Yamagata 37.0
Brazil Yamagata (15; 4.6) Yamagata 42.3
2009
South America – Yamagata –
Brazil – Yamagata –
2010
South America Victoria (103; 1.0) Victoria 1.9
Brazil – Victoria –
2011
South America Victoria (6; 0.1) Victoria 0
Brazil – Victoria –
2012
South America Yamagata (489; 4.5) Victoria 50.5
Brazil – Victoria –
2013
South America Victoria (364; 1.8) Yamagata 52.0
Brazil Victoria (32; 0.7) Yamagata 91.4
2014
South America Yamagata (252; 3.7) Yamagata 9.7
Brazil – Yamagata –
Note:  Data taken from WHO/FluNet (07 September, 2014).19 “–” indicates that data is not available for this year.
a Percentages are representative of the predominating lineage which are estimated with the total number of samples positive for inﬂuenza Bas the denominator.
b % Mismatch = 100% − % Circulating B lineage match with vaccine.
that in 2013, a high degree of mismatch between the vaccine
and the predominating circulating lineage (91.4%) occurred,
and during the other two inﬂuenza seasons, a partial mis-
match was reported.
The three reviewed abstracts, which speciﬁcally report
ﬁndings on inﬂuenza B mismatch, corroborate this unpre-
dictable behavior of inﬂuenza B disease in Brazil for many
other seasons for which data were not available in the Inter-
national Epidemiological surveillance data. Signiﬁcant levels
of co-circulation of both inﬂuenza B lineages (B/Victoria and
B/Yamagata) and lineage mismatch between the vaccine and
circulating lineage was reported for Brazil in ﬁve inﬂuenza
seasons (2002, 2005, 2008, 2010, and 2013).42–44 Previous stud-
ies suggest that even with a partial mismatch over the years,
due to the unpredictability of inﬂuenza B lineage circulation,
the disease burden (in terms of clinical cases, hospitalizations
and health care resource utilization) and societal burden can
be considerable.2,9 For example, a mismatch in the 2007–2008
inﬂuenza season in the United States was estimated to have
costed health care providers and society well over $100 mil-
lion and $1 billion, respectively.45 In another study conducted
in Taiwan, it was reported that an epidemic predominated by
inﬂuenza B/Yamagata lineage occurred during the 2011–2012
season during which the trivalent inﬂuenza vaccine contained
inﬂuenza B/Victoria lineage. Expectedly, the morbidity and
mortality of this vaccine mismatched epidemic was substan-
tial (inﬂuenza B: 60.7% and 66.9% of conﬁrmed inﬂuenza casesand deaths, respectively; 87.2% of samples showed the pres-
ence of vaccine opposite lineage).46
Surveillance data on the age distribution of inﬂuenza cases
is available only for 2013. This data showed that inﬂuenza
B virus was predominantly observed in younger individuals
aged 5–29 years, with the highest proportions in children aged
5–9 years and 10–19 years. Even though this observation was
restricted to only one year with 90% mismatch it is in line
with previous reports wherein inﬂuenza B has been reported
to affect more  schoolchildren and the appearance of the new B
lineage reinforced this pattern.4 An implication of this ﬁnding
is that children and adolescents might beneﬁt the most from
the addition of a second inﬂuenza B lineage to the seasonal
inﬂuenza vaccine. Moreover, it could be useful for the entire
population as it is widely considered that vaccinating children
can reduce inﬂuenza illness in family members and other sus-
ceptible populations in the community by reducing the risk
of exposure and subsequent inﬂuenza infection and related
complications.47 A similar ﬁnding by Heikkinen et al.10 reports
a substantial population-level impact of outbreaks resulting
from mismatched seasons in Finland with this impact pre-
dominating in children and adolescents.
From the analysis of the Epidemiological Bulletins of the
Brazilian MoH  based on two types of surveillance systems in
Brazil, it is shown that the proportions of ILI and SARS cases
positive for inﬂuenza B were moderate. It was observed that
despite high levels of vaccination coverage (91.6%) observed
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cross all target groups in 2013,13 the proportion of registered
ARS cases due to inﬂuenza B in 2013 was 22.5% (1337/5935;
niversal SARS surveillance), a year in which 91.4% of the
nﬂuenza B laboratory samples did not correspond to the lin-
age contained in the trivalent vaccine (WHO/FluNet). In the
ame year, 85 deaths due to inﬂuenza B were registered. This
ccurrence could have been due to an outbreak of SARS caused
y inﬂuenza B. It was demonstrated by Matias et al.11 that
nﬂuenza B-associated mortality could potentially be a valid
ndication of disease severity. Thus the evidence presented
ere for one year underscores the importance of a universal
nﬂuenza vaccination strategy compared to targeted immu-
ization as universal immunization at high vaccine coverage
evels could potentially interrupt transmission reducing the
ccurrence of outbreaks and severe disease.
Our literature review conﬁrms the re-emergence of
/Victoria lineage in Brazil during the years 2000–2002. These
ata are in line with that of Motta et al.48 which shows the
e-emergence of the Victoria-lineage viruses in the North-
rn hemisphere and in the South and South East regions
f Brazil where previously the B/Yamagata lineage was the
redominating circulating lineage and the vaccine recom-
ended lineage. Other studies conﬁrm that the B/Yamagata
as the major circulating lineage until the 1980s, when
/Victoria lineage viruses appeared; since then, drift vari-
nts of both inﬂuenza B lineages have been co-circulating
orldwide.49,50 As inﬂuenza B viruses can co-circulate during
n epidemic allowing the re-emergence of old lineages due to
e-assortment between the different strains,4,48 there is a needto improve inﬂuenza laboratory-based surveillance in Brazil.
Importantly these data also highlight the unpredictability of
inﬂuenza B circulation, making it difﬁcult to consistently pre-
dict which B lineage will predominate during a given inﬂuenza
season.
Due to the little cross-protection conferred between the
two antigenically distinct inﬂuenza B lineages, a vaccine
lineage mismatch with the circulating lineage could result
in additional burden in terms of health care resource uti-
lization and can adversely impact the society. This burden
could, in particular, be substantial during an outbreak. To
avoid this additional burden, a plausible option would be
to switch from the use of trivalent inﬂuenza vaccines to
quadrivalent vaccines in national campaigns.51 Quadrivalent
inﬂuenza vaccines are expected to offer broader protection
against inﬂuenza B disease. The WHO  recently updated rec-
ommendations beginning with the 2013–2014 inﬂuenza, now
recommending the use of a quadrivalent vaccine composition
with the addition of a second inﬂuenza B lineage as well as the
two inﬂuenza A strains and one inﬂuenza B lineage contained
in the trivalent vaccines.6,52
Some limitations of this review require consideration.
Besides the inherent limitations of each of the studies
included in the literature search and abstracts, there are
other important limitations. Statistical and quality analysis
of the articles was not performed. Also, the interpretation of
data is constrained by the gaps in laboratory surveillance in
which there were no inﬂuenza B data available for many  years
with respect to age, severity, and seasonality. As we  present
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data over many  years through which the surveillance system
has gradually improved, the number of positive samples is
still small, and the more  recent years are likely to be over-
represented. Additionally, sentinel surveillance data cannot
be truly representative for the whole population as the system
of sentinel units involves different levels of care. Moreover,
there is no standard protocol for patient selection for sample
collection which may have led to a selection bias of certain age
groups. Despite these limitations, the surveillance system for
inﬂuenza and other respiratory viruses which has improved
over the years has proven useful to describe inﬂuenza B cir-
culation patterns for Brazil and demonstrate that inﬂuenza B
epidemiology is changing in line with observations reported
from other countries.4
Conclusions
Inﬂuenza surveillance systems, and laboratory-based and epi-
demiological studies of inﬂuenza B in Brazil, while limited,
have improved over the years. There is a need to strengthen
and extend inﬂuenza surveillance for inﬂuenza B sample
subtyping to determine the behavior pattern of inﬂuenza B lin-
eages. The ﬁndings from this integrative data review provide
evidence of the unpredictable nature of inﬂuenza B circula-
tion in Brazil, the increasing frequency of co-circulation of
both inﬂuenza B lineages, and mismatch between the circu-
lating inﬂuenza B lineage and the composition of the seasonal
inﬂuenza vaccine for the region. This data is suggestive of the
additional beneﬁt that quadrivalent inﬂuenza vaccines, con-
taining both inﬂuenza B lineages (B/Yamagata and B/Victoria),
could offer over the use of the currently available trivalent
vaccines for the prevention of seasonal inﬂuenza in Brazil.
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